Liposome News and Research

Latest Liposome News and Research

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

A new study suggested that an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine induced mucosal immune responses in mice.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

New study to investigate focused ultrasound's role in addressing neurofibromatosis type 2

The Focused Ultrasound Foundation and the Children's Tumor Foundation (CTF) have established a partnership to advance innovative, noninvasive treatments in pediatrics.

21 Jul 2022

Scientists combine robotics with biology to construct biohybrid microrobots

A team of scientists in the Physical Intelligence Department at the Max Planck Institute for Intelligent Systems have combined robotics with biology by equipping E. coli bacteria with artificial components to construct biohybrid microrobots.

15 Jul 2022

Liposomes tailored for pulmonary delivery for treating acute respiratory distress syndrome

Researchers developed 1,2-dimpalmiyristoyl-sn-glycero-3-phosphocholine liposomes co-loaded with methylprednisolone and N-acetyl cysteine to treat acute respiratory distress syndrome in vivo.

31 Mar 2022

Scientists assemble carbon nanotubes in a new way to deliver cancer drugs

Fundamental science often finds applications beyond its original focus. Previously, scientists found applications for small diameter carbon nanotube porins in energy technology.

29 Jan 2022

Curia unveils comprehensive mRNA solution

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle formulation and development for full-scale sterile fill-finish services.

From Curia Global, Inc. 7 Jan 2022

Research suggests targeting fusion peptide-calcium interaction may help treat COVID-19

Researchers discovered that the entry of coronaviruses is a Ca2+-dependent process and focused their studies on the SARS-1 FP-Ca2+ interaction and its effect on membranes using electron spin resonance (ESR).

10 Dec 2021

Freeze-dried liposomes could be used in potential COVID-19 vaccines

Things that are freeze-dried: Astronaut food. Emergency rations. And, just maybe, some future COVID-19 vaccines.

1 Dec 2021

Scientists pave the way for creating 'mini biological computers' in droplets

Scientists have worked out how to best get DNA to communicate with membranes in our body, paving the way for the creation of 'mini biological computers' in droplets that have potential uses in biosensing and mRNA vaccines.

18 Oct 2021

ICL fluorescent label homogenously penetrates the glioblastoma brain tumors

Fluorescent indocarbocyanine lipid (ICL) shows much better distribution within glioblastoma brain tumors compared to fluorescent phospholipids, according to a study published in ACS Nano.

23 Aug 2021

Study examines the effectiveness of fluorescent labels used to monitor liposome accumulation in tumors

Dmitri Simberg, PhD, an associate professor in the Department of Pharmaceutical Sciences in the Skaggs School of Pharmacy and a CU Cancer Center member, has released the results of a new study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors.

8 Jul 2021

Precision medicine may lead to more effective treatments for ocular conditions

The most practical solution for drug delivery to the eyeball is topical, i.e. eye drops. However, a naturally occurring substance in tears actually can interact with the drug delivery system (DDS), hindering absorption of the drug and preventing it from getting into the cells it needs to target.

17 Jun 2021

The Role of Nanoparticles for Drug Delivery

In this interview, Mark Bumiller, Technology Manager at Entegris talks to News Medical Life Sciences about the role nanoparticles can play in drug delivery.

From Entegris, Inc. 15 Jun 2021

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

In a recent bioRxiv* preprint research paper, M. Gordon Joyce et al. designed engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion Spike (S), S1 and receptor-binding domain (RBD). They demonstrated that these immunogens induced robust S-binding, ACE2 (angiotensin-converting enzyme)-inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2 in mice.

13 May 2021

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Researchers have developed a promising new anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)vaccine candidate that utilizes nanotechnology and shows robust, long-lived immunity in mouse models.

5 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

15 Mar 2021

Novel method instructs immune cells to help repair damaged tissues in the intestine

A method that instructs immune system cells to help repair damaged tissues in the intestine has been developed by researchers at KU Leuven and Seoul National University.

8 Feb 2021